Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
SciBase Holding AB's operating assets for the quarter that ended in Mar. 2026 was kr32.44 Mil. SciBase Holding AB's operating liabilities for the quarter that ended in Mar. 2026 was kr21.65 Mil. SciBase Holding AB's Total Assets for the quarter that ended in Dec. 2025 was kr52.17 Mil. Therefore, SciBase Holding AB's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.21.
SciBase Holding AB Scaled Net Operating Assets Related Terms
SciBase Holding AB Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for SciBase Holding AB's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SciBase Holding AB Scaled Net Operating Assets Chart
OSTO:SCIB vs ABT, SYK, MDT: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, SciBase Holding AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciBase Holding AB Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SciBase Holding AB's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where SciBase Holding AB's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.21 mean?
SciBase Holding AB (OSTO:SCIB) has a Scaled Net Operating Assets of 0.21 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on SciBase Holding AB and its competitors.
Is SciBase Holding AB's Scaled Net Operating Assets too high?
SciBase Holding AB's current Scaled Net Operating Assets is 0.21. Overall, SciBase Holding AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciBase Holding AB's Scaled Net Operating Assets compare to ABT and SYK?
SciBase Holding AB's Scaled Net Operating Assets of 0.21 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on SciBase Holding AB and its competitors. SciBase Holding AB's current Scaled Net Operating Assets is 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciBase Holding AB stock overvalued right now?
Based on GuruFocus' analysis, SciBase Holding AB (OSTO:SCIB) is currently considered Significantly Overvalued. The stock's GF Value™ is kr21.74, compared to a current price of kr33.80 — trading 55.5% above its estimated fair value. The current Scaled Net Operating Assets is 0.21. SciBase Holding AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For SciBase Holding AB (OSTO:SCIB), the current Scaled Net Operating Assets is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciBase Holding AB (OSTO:SCIB) Overvalued in 2026?
Based on GuruFocus' analysis, SciBase Holding AB stock appears to be overvalued.
The current stock price of kr33.80 is trading 55.5% above its estimated GF Value™ of kr21.74.
GuruFocus considers SciBase Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:SCIB:
Scaled Net Operating Assets: 0.21
GF Value™: kr21.74 vs. price of kr33.80 (55.5% above fair value)
No single metric tells the full story. See the OSTO:SCIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciBase Holding AB is a medical technology company specializing in early detection of skin cancer and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a point-of-care technology platform that combines AI (artificial intelligence) and EIS technology to elevate diagnostic accuracy and support the prevention of skin diseases. The company's product portfolio consists of the Nevisense platform technology for multiple clinical applications and proprietary Nevisense electrodes. The products are based on measurements using electrical impedance spectroscopy (EIS), analysed using custom artificial intelligence (AI)-based algorithms. The company operates in two segments, which include skin cancer and skin barrier assessment.
50GF Score
Get the complete analysis for OSTO:SCIB
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SCIB has been successfully added to your 
